预约演示
更新于：2025-05-16
Cilastatin Sodium/Imipenem
西司他丁钠/亚胺培南
更新于：2025-05-16
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H43N5NaO9S2 |
InChIKeyXWIKEETXNRMEDP-KJWPAVRRSA-N |
CAS号85960-17-4 |
关联
24
项与 西司他丁钠/亚胺培南 相关的临床试验TCTR20250410003
Efficacy and Safety of direct drug provocation test in children with benign cutaneous immediate hypersensitivity reaction to Beta-lactams
ChiCTR2300078079
Clinical detection of plasma concentration of imipenem cilastatin sodium based on fluorescent probe molecules
CTR20222694
一项评估注射用亚胺培南/西司他丁-XNW4107与亚胺培南/西司他丁/瑞来巴坦相比治疗成人医院获得性细菌性肺炎或呼吸机相关细菌性肺炎的有效性和安全性的多中心，随机，双盲，对照的III期临床研究
100 项与 西司他丁钠/亚胺培南 相关的临床结果
登录后查看更多信息
100 项与 西司他丁钠/亚胺培南 相关的转化医学
登录后查看更多信息
100 项与 西司他丁钠/亚胺培南 相关的专利（医药）
登录后查看更多信息
5,244
项与 西司他丁钠/亚胺培南 相关的文献（医药）2025-08-01Current Drug Safety
Imipenem-Cilastatin-Induced Seizures: A Case Report
Article
作者: Houria, Baraa Ben ; Yousfi, Mohamed Ali ; Aloui, Ghaith
Background::
Imipenem-cilastatin, a carbapenem antibiotic, is commonly used for severe
bacterial infections. While generally well-tolerated, it can rarely cause central nervous system
toxicity, including seizures. We have, herein, reported a case of imipenem-cilastatin-induced
seizure in a 20-year-old patient.
Case Presentation::
A 20-year-old male was admitted to the intensive care unit for febrile status
epilepticus and acute respiratory distress syndrome. Initial evaluations ruled out underlying causes
and anti-epileptic treatment has been initiated. Despite having an effective anti-epileptic treatment
for three months of hospitalization, seizure recurrence occurred, leading to antibiotic regimen adjustment
as the imputability of imipenem-cilastatin was suspected. After discontinuation of the involved
drug, the patient remained neurologically stable. Previous literature has reported cases of
imipenem-cilastatin-induced seizures, particularly in elderly patients or at higher dosages. The
causality assessment was conducted using the updated French method, which rated the chronological
criterion as C2 and the semiological criterion as S2. The intrinsic imputability score was I3, indicating
plausible causality, and the extrinsic bibliographic score was B3.
Conclusion::
Conclusion: Our case has highlighted the importance of promptly recognizing imipenem-cilastatin-
induced epileptic seizures in order to treat them more effectively and thus optimize the patient’s
care. Therefore, we emphasize that clinicians be vigilant about the side effects of its use, particularly
in patients with neurological susceptibilities. We also advocate a personalized choice of
antibiotics, taking into account both antimicrobial efficacy and potential adverse effects, for better
outcomes with fewer risks.
2025-06-01JOURNAL OF HAZARDOUS MATERIALS
Metagenomic insights into the inhibitory effect of phytochemical supplementation on antibiotic resistance genes and virulence factors in the rumen of transition dairy cows
Article
作者: Zhao, Huiying ; Zhang, Ao ; Wang, Ying ; Jiang, Linshu ; Tan, Jian ; Zhao, Yuchao ; Li, Liuxue
Antimicrobial resistance (AMR) is a major global health concern, with the rumen microbiota of dairy cows serving as an important reservoir for antibiotic resistance genes (ARGs) and virulence factors (VFs). This study explores the impact of dietary phytochemical supplementation on the rumen resistome and virulome of transition dairy cows using metagenomic sequencing. Naringin supplementation reduced the abundance of ARGs by up to 9.0 % and VFs by up to 7.2 % during the transition period, as indicated by metagenomic analysis (P < 0.05). Clinically high-risk ARGs, including those conferring resistance to beta-lactams (mecA), tetracyclines (tetM, tetO), and aminoglycosides (rmtF), were notably downregulated (P < 0.05). Virulence factors associated with adherence, secretion systems, and toxins were also significantly decreased (P < 0.05). Naringin altered the microbial community structure, particularly reducing the abundance of Proteobacteria, a key phylum harboring ARGs and VFs. Despite inducing increased ARG-VF network complexity, naringin supplementation promoted a less pathogenic microbiome with reduced resistance potential. These findings demonstrate the potential of naringin as a natural dietary strategy to mitigate AMR by reducing the risk of ARG and VF dissemination into the environment, while supporting rumen microbiota stability in transition dairy cows.
2025-06-01EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Correction to: Effectiveness of Macrolides as Add-On Therapy to Beta-Lactams in Community-Acquired Pneumonia: A Meta-Analysis of Randomized Controlled Trials
作者: Mendes, Beatriz Ximenes ; de Hollanda Morais, Beatriz Austregésilo de Athayde ; de Moura Souza, Mariana ; Prizão, Vitória Martins ; Martins, Otavio Cosendey ; Defante, Maria Luiza Rodrigues
Abstract: Purpose: This study aims to evaluate whether adding macrolides (MAC) to beta-lactam (BL) monotherapy in the treatment of community-acquired pneumonia (CAP) offers clin. benefits that justify the potential disadvantages or side effects.Methods: We systematically searched PubMed, Embase, and Cochrane for randomized controlled trials (RCTs) comparing BL monotherapy to combination therapy with BL and MAC for the in-hospital treatment of CAP.We pooled mean differences (MD) for continuous outcomes and risk ratio (RR) for binary outcomes, with 95% confidence intervals (CI).Results: Six RCTs with 2661 participants (52% receiving combination therapy), revealed no significant difference in in-hospital mortality (RR 0.99; 95% CI 0.78 to 1.25; p = 0.94; I2 = 0%), 90-day mortality (RR 1.03; 95% CI 0.82 to 1.29; p = 0.83; I2 = 13%), or 30-day mortality (RR 0.90; 75% CI 0.63 to 1.29; p = 0.58; I2 = 54%).Addnl., no significant differences were observed in the length of hospital stay (MD 0.51; 95% CI - 0.50 to 1.51; p = 0.33; I2 = 63%) or respiratory insufficiency (RR 0.63; 95% CI 0.29 to 1.35; p = 0.24; I2 = 74%).However, combination therapy significantly improved the treatment success rate (RR 1.17; 95% CI 1.04 to 1.32; p = 0.009; I2 = 0%).Conclusion: Our findings suggest that BL + MAC therapy should not be used in all cases of hospitalized patients with CAP.PROSPERO ID: CRD42024516383 - Data of registration: 03/03/2024.
100 项与 西司他丁钠/亚胺培南 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 西司他丁钠/亚胺培南 | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细菌感染 | 中国 | 2000-05-27 | |
| 骨和关节感染 | 美国 | 1985-11-26 | |
| 心内膜炎 | 美国 | 1985-11-26 | |
| 妇科感染 | 美国 | 1985-11-26 | |
| 感染 | 美国 | 1985-11-26 | |
| 腹腔感染 | 美国 | 1985-11-26 | |
| 下呼吸道感染 | 美国 | 1985-11-26 | |
| 脓毒症 | 美国 | 1985-11-26 | |
| 皮肤和皮肤结构感染 | 美国 | 1985-11-26 | |
| 泌尿道感染 | 美国 | 1985-11-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 10 | Transcatheter arterial embolization using imipenem/cilastatin | 憲鬱蓋艱範壓觸廠艱艱(夢壓夢齋淵鑰鬱積繭膚) = there was no pain relapse in 6 months, and patients did not require any other form of therapy 鏇衊廠憲醖遞窪糧鑰襯 (餘衊壓齋憲鹹簾餘獵願 ) | 积极 | 2024-02-28 | ||
临床4期 | 470 | 衊鑰觸糧觸鹽糧觸遞遞(觸窪網鑰簾鏇糧齋鹹壓) = nausea, drug ineffectiveness, postoperative wound infection, vomiting, and pyrexia were the most common adverse events in tigecycline-treated subjects 築窪廠夢築鹽網鹽願糧 (構製淵鹹鏇遞鹹廠獵觸 ) 更多 | - | 2018-01-01 | |||
N/A | - | 憲淵壓膚製壓齋鏇簾膚(繭艱鏇簾願積觸鏇繭襯) = 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack 衊鏇繭願壓齋鬱壓遞構 (廠鏇遞衊餘齋蓋鹽繭廠 ) | - | 2000-01-01 | |||
N/A | - | - | 繭顧壓糧願餘築餘糧蓋(願餘廠憲觸遞壓構夢鑰) = 鏇鏇憲餘憲簾糧淵構觸 簾齋憲鹹餘糧選築範網 (製築顧鹽繭鏇顧廠壓鏇 ) | - | 1988-01-01 | ||
繭顧壓糧願餘築餘糧蓋(願餘廠憲觸遞壓構夢鑰) = 鬱選繭願鹽獵鹹糧艱壓 簾齋憲鹹餘糧選築範網 (製築顧鹽繭鏇顧廠壓鏇 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用